Equities Analysts Offer Predictions for SRTS Q2 Earnings

Key Points

• HC Wainwright has reduced its Q2 2026 earnings per share estimate for Sensus Healthcare from $0.03 to ($0.01), maintaining a "Buy" rating with a price target of $8.00.
• Institutional investors have shown interest in Sensus Healthcare, acquiring significant new stakes, with institutionals now holding 25.30% of the company's stock.
• For its most recent quarter, Sensus Healthcare reported ($0.06) earnings per share, missing the consensus estimate and generating revenue of $7.32 million, which was below expectations.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Equities researchers at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for Sensus Healthcare in a research note issued to investors on Tuesday, August 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.01) per share for the quarter, down from their previous forecast of $0.03. HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share.

A number of other research firms have also recently commented on SRTS. Lake Street Capital cut their target price on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd. Finally, Maxim Group lowered their target price on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th.

Sensus Healthcare Stock Performance

SRTS opened at $3.32 on Wednesday. The stock has a market cap of $54.52 million, a price-to-earnings ratio of -52.85 and a beta of 1.34. The stock's 50 day moving average price is $4.78 and its 200-day moving average price is $4.95. Sensus Healthcare has a one year low of $3.03 and a one year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.56% and a negative net margin of 2.26%. The company had revenue of $7.32 million for the quarter, compared to the consensus estimate of $9.30 million.

Institutional Trading of Sensus Healthcare

A number of institutional investors have recently made changes to their positions in SRTS. Larson Financial Group LLC acquired a new stake in shares of Sensus Healthcare in the 1st quarter worth $26,000. JPMorgan Chase & Co. acquired a new stake in shares of Sensus Healthcare in the 4th quarter worth $27,000. Barclays PLC acquired a new stake in shares of Sensus Healthcare in the 4th quarter worth $35,000. BNP Paribas Financial Markets purchased a new position in Sensus Healthcare in the 4th quarter worth $47,000. Finally, Vise Technologies Inc. purchased a new position in Sensus Healthcare in the 2nd quarter worth $52,000. Institutional investors and hedge funds own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.